Sales & Marketing

AbbVie acquiring all outstanding shares of ImmunoGen, Inc. for $31.26 per share, valuing the company at a total equity value of approximately $10.1 billion.

Capan discusses the industry is embracing new technologies and how these use cases may evolve in the coming year.

Heliyon study evaluates online information, labeling accuracy, and quantitative analysis of high peroxide content gels.

Dozens of companies are selling stem cell treatments and exosome therapies that have not been approved for use or authorized for emergency use by the FDA.

Novo Nordisk said it will continue providing Levemir vials and the Levemir FlexPen for diabetes control while supplies last, until the full product discontinuation at the end of 2024.

Webinar Date/Time: Wed, Dec 6, 2023 2:00 PM EST

C-Suites and their boards should remember that digital transformation is a key part of the larger focus of a profound business transformation.

Glyburide and metformin are active ingredients in several prescription-only medications indicated for the treatment of patients with type 2 diabetes.

The rise in popularity of GLP-1 weight-loss drugs, such as Ozempic, Wegovy, and Mounjaro, has had a wide-reaching impact across the healthcare industry and beyond.

The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers.

New subsidiary specializes in development of oral liquid products.

In the ever-evolving landscape of healthcare, it's vital for organizations to take steps toward bridging the gap between their clinical and marketing teams.

Collaboration aims to expand space research in studies of heart disease and diabetes.

Joint venture aims to seamlessly deliver Dyanavel through Perigon’s digital pharmacy.

Merger expected to expand company’s existing complementary platform of organ manufacturing programs.

Treatment marks company’s first approval for a type of inflammatory bowel disease.

Parties will establish a Center of Excellence in CMIC’s NJ plant.

Company aims to develop functional antibodies for the treatment of immunological & inflammatory disorders.

Agreement aims to speed up the launch of endometriosis and androgenic alopecia treatment.

Collaboration to focus on advancing mRNA-based oncology therapeutics.

Company to discuss acquisition and expansion of executive leadership.

Collaboration to focus on biologics of Kurma’s portfolio companies.

Investigational therapy indicated for the treatment of systemic sclerosis.

New company to be publicly listed as Citius Oncology, Inc.

Deal includes rights to novel antibody for the treatment of inflammatory bowel disease.